Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.

Danielle C GlassmanRandze L PalmairaChristina M CovingtonAvni M DesaiGeoffrey Y KuJia LiJames J HardingAnna M VargheseEileen M O'ReillyKenneth H Yu

Published in: BMC cancer (2018)

These data support the safety and efficacy of nal-IRI + 5-FU/LV, reinforcing results of NAPOLI-1. Patients without disease progression on prior irinotecan fared significantly better than patients with progression, when treated with nal-IRI + 5-FU/LV. Sequential therapy with nab-P + Gem followed by nal-IRI + 5-FU/LV demonstrates encouraging median OS. These findings provide guidance for patients most likely to benefit from nal-IRI + 5-FU/LV.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
machine learning
mesenchymal stem cells
patient reported outcomes
bone marrow
cell therapy
tyrosine kinase
replacement therapy